Ann Arbor, Michigan 48109


Anterior cruciate ligament (ACL) tears are among the most frequent traumatic knee injuries that occur in physically active individuals. Despite advances in minimally invasive surgical reconstruction techniques and aggressive rehabilitation, this atrophy and loss of strength can persist even after patients return to full activity and can place them at considerable risk for re-injury and developing osteoarthritis (OA). The design of new therapeutic interventions to prevent muscle atrophy is needed to advance the care of patients who suffer from ACL injuries. The growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis plays an important role in promoting muscle growth and protecting muscle from atrophy. While GH therapy has shown promise in protecting immobilized muscle from various models of disuse atrophy, it remains unknown whether GH can help to restore strength and protect against the loss in strength that occurs after ACL tear. GH therapy may help to accelerate the safe return to play of patients that suffer ACL tears, and help to prevent the long-term OA and reduction in quality of life that occur after these traumatic knee injuries.


Inclusion Criteria: - Males between the ages of 18 and 35 - Have acute unilateral complete ACL tears with or without bucket handle medial meniscus tears that occurred within the past 6 months - Consent to undergo an ACL reconstruction by an orthopaedic surgeon using a patellar tendon or hamstring autograft - Will be performing supervised post-operative rehabilitation at UMHS MedSport at Dominos Farms Exclusion Criteria: - Patients who are undergoing a revision ACL reconstruction - Had a previous injury to the involved knee - Have an allergy to recombinant GH - Have a BMI<20 or >35 - Have a growth disorder of bones or connective tissue, type 1 diabetes mellitus, type 2 diabetes mellitus, or who have a history of carpal tunnel syndrome, trigger finger, myopathy, cancer, endocrine disorder, hypertension or rheumatologic disorder. - Systolic blood pressure >140mm Hg or diastolic blood pressure >90mm Hg, or with resting heart rate >110 BPM or <40 BPM at screening. - Additionally, because GH is currently listed as a banned substance by the World Anti-Doping Agency (WADA), National Collegiate Athletics Association (NCAA) and most professional sports agencies, we will exclude patients who are current collegiate, professional or elite athletes.



Primary Contact:

Principal Investigator
Christopher L Mendias, PhD, ATC
University of Michigan

Elizabeth Sibilsky Enselman, MEd, ATC
Phone: 734 930-7386

Backup Contact:

Jaimee Gauthier, BS
Phone: 734 647-0050

Location Contact:

Ann Arbor, Michigan 48109
United States

Elizabeth R Sibilsky Enselman, MEd, ATC
Phone: 734-930-7386

Site Status: Recruiting

Data Source:

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.